ClinicalTrials.gg
CompletedNCT02660580AURIEL-PsOUpdated Dec 27, 2023Results posted

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of MSB11022 and Humira® in Psoriasis, Plaque Type Psoriasis and Moderate to Severe Plaque Psoriasis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 76 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
7th of 48
443 · median 148
Started
2016
with 2 others
Phase 3
26 of 48
1 open now
Registered
34th of 48
by date

Among the 48 studies testing adalimumab in Psoriasis, this one is the 7th largest by enrollment, is one of 3 that started in 2016, is one of 26 in phase 3, and was the 34th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.

03

Conditions studied

  • Psoriasis
  • Plaque Type Psoriasis
  • Moderate to Severe Plaque Psoriasis

Browse trials for

Keywords

  • Adalimumab
  • MSB11022
  • Psoriasis
  • Phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants greater than or equal to (>=) 18 years old with a clinical diagnosis of stable moderate to severe plaque psoriasis (defined by Psoriasis Area and Severity Index [PASI] score >=12, Physician Global Assessment [PGA] score >=3, and >=10% of body surface area affected at Screening and Baseline [Day 1 of Week 1]) who have a history of receipt of or are candidates for systemic therapy or phototherapy for active plaque-type psoriasis despite topical therapy
  • Participants must not have received more than 1 biologic therapy
  • Other protocol-defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants was excluded if they have erythrodermic, pustular, guttate, or medication-induced forms of psoriasis or other active skin diseases/infections that may interfere with the evaluation of plaque psoriasis
  • Participants must not have received adalimumab or an or licensed biosimilar of adalimumab; topical therapies for the treatment of psoriasis or ultraviolet B phototherapy within 2 weeks of investigational medicinal product (IMP) administration or plan to take such treatment during the trial; or psoralen combined with ultraviolet A phototherapy or nonbiological systemic therapies for psoriasis within 4 weeks prior to IMP administration
  • Participants was excluded if they have a history of an ongoing, chronic, or recurrent infectious disease (except for latent tuberculosis [TB]); history of active TB; or a history of to any component of the IMP formulation, comparable drugs, or latex
  • Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    MSB11022 (Core Treatment Period)

    Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.

    Drug: MSB11022

  • Active comparator
    EU-Humira

    Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.

    Drug: Humira®

  • Experimental
    MSB11022 (Extended Treatment Period)

    Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.

    Drug: MSB11022

  • Active comparator
    EU-Humira/EU-Humira

    Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.

    Drug: Humira®

  • Experimental
    EU-Humira/MSB11022

    Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.

    Drug: MSB11022 · Drug: Humira®

Interventions

  • Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.

  • Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI-75 response is defined as the percentage of participants who achieved at least a 75% improvement in PASI score from Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change From Baseline in PASI at Week 16

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Percent change from Baseline in PASI score was reported.

    Time frame: Baseline (Day 1 of Core Treatment Period), Week 16

  2. Percentage of Participants Who Achieved PASI 50, 90 and 100 at Week 16

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI 50, 90 and 100 response rate at Week 16 is measured as the percentage of participants who achieved at least 50, 90 and 100% improvement from baseline PASI score at Week 16.

    Time frame: Week 16

  3. Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 24

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 24 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 24.

    Time frame: Week 24

  4. Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 52

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 52 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 52.

    Time frame: Week 52

  5. Percent Change From Baseline in PASI at Week 24 and 52

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity.

    Time frame: Baseline (Day 1 of Extended Treatment Period), Weeks 24 and 52

  6. Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 16

    PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates Clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates Mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates Moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates Severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

    Time frame: Baseline (Day 1 of Core Treatment Period), Week 16

  7. Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 24 and 52

    PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

    Time frame: Baseline (Day 1 of Extended Treatment Period), Week 24 and 52

  8. Time to Achieve PASI 50

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 50% improvement in PASI from baseline was measured.

    Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4

  9. Time to Achieve PASI 75

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 75% improvement in PASI from baseline was measured.

    Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4

  10. Time to Achieve PASI 90

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 90% improvement in PASI from baseline was measured.

    Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4

  11. Time to Achieve PASI 100

    PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 100% improvement in PASI from baseline was measured.

    Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 13.5

  12. Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 16

    PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

    Time frame: Baseline (Day 1 of Core Treatment Period), Week 16

  13. Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 24

    PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

    Time frame: Baseline (Day 1 of Extended Treatment Period), Week 24

  14. Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 52

    PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

    Time frame: Baseline (Day 1 of Extended Treatment Period), Week 52

  15. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 16

    Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline (Day 1 of Core Treatment Period) up to Week 16

  16. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 54

    Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline (Day 1 of Extended Treatment Period) up to Week 54

  17. Number of Participants With Clinically Meaningful Differences in Laboratory Values

    Based on categories of low, normal, or high according to the laboratory normal ranges, there were no clinically meaningful differences across the treatment groups in the numbers of participants with shifts in Laboratory parameters including hematology, chemistry and urinalysis from normal at Core Baseline to either low or high during the overall treatment period. Clinical meaningful was determined by the investigator.

    Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54

  18. Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 16

    Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.

    Time frame: Week 16

  19. Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 24, 32, 40 and 52

    Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.

    Time frame: Week 24, 32, 40 and 52

  20. Number of Participants With Clinically Meaningful Differences in Vital Signs

    Number of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.

    Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54

  21. Number of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG)

    Number of participants with clinically significant abnormalities in 12-ECG were reported. Clinical significance was determined by the investigator.

    Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54

  22. Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).

    Time frame: Weeks 16

  23. Dermatology Life Quality Index (DLQI) at Week 24 and 52

    The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).

    Time frame: Week 24 and 52

  24. European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 16

    The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).

    Time frame: Week 16

  25. European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 24 and 52

    The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).

    Time frame: Week 24 and 52

  26. European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 16

    The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

    Time frame: Week 16

  27. European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on VAS Score at Week 24 and 52

    The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

    Time frame: Week 24 and 52

  28. Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 16

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Week 16

  29. Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24, and 52

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Week 24 and 52

  30. Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 16

    Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.

    Time frame: Week 16

  31. Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 24 and 52

    Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.

    Time frame: Week 24 and 52

  32. Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 16

    Number of participants with treatment emergent Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab were reported from baseline to week 16. Data was collected using validated bioanalytical method.

    Time frame: Week 16

  33. Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 24, 32, 40 and 52

    Number of participants With positive treatment emergent Anti-Drug Antibodies (ADAs) and positive Neutralizing Antibodies (NAbs) to Adalimumab were reported. Data was collected using validated bioanalytical method.

    Time frame: Week 24, 32, 40 and 52

  34. Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 16

    Anti-Drug Antibodies (ADAs) Titers for adalimumab at week 16 was reported. Data was collected using validated bioanalytical method.

    Time frame: Week 16

  35. Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 24, 32, 40 and 52

    Anti-Drug Antibodies (ADAs) Titers for adalimumab at Week 24, 32, 40 and 50 was reported. Data was collected using validated bioanalytical method.

    Time frame: Week 24, 32, 40 and 52

  36. Observed Serum Concentration at Week 16

    Observed serum concentrations at week 16 were reported.

    Time frame: Week 16

  37. Observed Serum Concentration at Week 24 and 52

    Observed serum concentrations at week 24 and 52 were reported.

    Time frame: Week 24 and 52

07

Results

Posted Feb 19, 2019

Participant flow

Core Treatment Period (Week 1 to 16)
Participant flow — Core Treatment Period (Week 1 to 16)
MilestoneMSB11022 (Core Treatment Period)EU-HumiraMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Started222221000
Treated221220000
Completed213202000
Not completed919000
Withdrew: Randomized, not treated11000
Withdrew: Protocol violation31000
Withdrew: Other un-specified10000
Withdrew: Lack of efficacy02000
Withdrew: Adverse event29000
Withdrew: Withdrawal by subject14000
Withdrew: Lost to follow-up12000
Extended Treatment Period(Week 16 to 52)
Participant flow — Extended Treatment Period(Week 16 to 52)
MilestoneMSB11022 (Core Treatment Period)EU-HumiraMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Started00213101101
Completed001959090
Not completed00181111
Withdrew: Protocol violation00201
Withdrew: Other un-specified00101
Withdrew: Lack of efficacy00422
Withdrew: Adverse event00864
Withdrew: Withdrawal by subject00322
Withdrew: Lost to follow-up00011

Outcome measures

SecondaryPercent Change From Baseline in PASI at Week 16

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Percent change from Baseline in PASI score was reported.

Time frame:
Baseline (Day 1 of Core Treatment Period), Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in PASI at Week 16
Percent changeMSB11022 (Core Treatment Period)EU-Humira
Percent Change From Baseline in PASI at Week 16-90.6 ± 11.3-91.7 ± 9.9
Statistical analysis
  • MSB11022 (Core Treatment Period) vs EU-Humira · Least square (ls) mean difference: 0.88 · 95% CI -1.21 to 2.98
SecondaryPercentage of Participants Who Achieved PASI 50, 90 and 100 at Week 16

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI 50, 90 and 100 response rate at Week 16 is measured as the percentage of participants who achieved at least 50, 90 and 100% improvement from baseline PASI score at Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved PASI 50, 90 and 100 at Week 16
Percentage of ParticipantsMSB11022 (Core Treatment Period)EU-Humira
PASI 50100.0100.0
PASI 9064.066.0
PASI 10033.037.2
SecondaryPercentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 24

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 24 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 24
Percentage of ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
PASI 50100.098.9100.0
PASI 7592.588.394.6
PASI 9074.078.780.4
PASI 10042.537.235.9
SecondaryPercentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 52

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 52 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 52.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 52
Percentage of ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
PASI 5097.8100.0100.0
PASI 7590.992.993.1
PASI 9076.378.885.1
PASI 10053.854.157.5
SecondaryPercent Change From Baseline in PASI at Week 24 and 52

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity.

Time frame:
Baseline (Day 1 of Extended Treatment Period), Weeks 24 and 52
Reported as:
Mean · Percent change
Percent Change From Baseline in PASI at Week 24 and 52
Percent changeMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 24-92.9 ± 9.9-91.3 ± 12.7-94.2 ± 8.2
Week 52-92.8 ± 13.6-93.9 ± 9.6-94.8 ± 9.7
SecondaryNumber of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 16

PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates Clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates Mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates Moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates Severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

Time frame:
Baseline (Day 1 of Core Treatment Period), Week 16
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 16
ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Baseline: Moderate; Week 16: Clear5251
Baseline: Moderate; Week 16: Almost clear7659
Baseline: Severe; Week 16: Clear1620
Baseline: Severe; Week 16: Almost clear2726
SecondaryNumber of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 24 and 52

PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

Time frame:
Baseline (Day 1 of Extended Treatment Period), Week 24 and 52
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 24 and 52
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Baseline: Moderate; Week 24: Clear692525
Baseline: Moderate; Week 24: AlmostClear522431
Baseline: Severe; Week 24: Clear18119
Baseline: Severe; Week 24: Almost Clear271413
Baseline: Moderate; Week 52: Clear742934
Baseline: Moderate; Week 52: AlmostClear401316
Baseline: Severe; Week 52: Clear291716
Baseline: Severe; Week 52: Almost Clear1566
SecondaryTime to Achieve PASI 50

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 50% improvement in PASI from baseline was measured.

Time frame:
Baseline (Day 1 of Core Treatment Period) up to Month 4
Reported as:
Median · Months
Time to Achieve PASI 50
MonthsMSB11022 (Core Treatment Period)EU-Humira
Time to Achieve PASI 501.6 ± 0.21.6 ± 0.2
SecondaryTime to Achieve PASI 75

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 75% improvement in PASI from baseline was measured.

Time frame:
Baseline (Day 1 of Core Treatment Period) up to Month 4
Reported as:
Median · Months
Time to Achieve PASI 75
MonthsMSB11022 (Core Treatment Period)EU-Humira
Time to Achieve PASI 752.5 ± 0.21.7 ± 0.7
SecondaryTime to Achieve PASI 90

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 90% improvement in PASI from baseline was measured.

Time frame:
Baseline (Day 1 of Core Treatment Period) up to Month 4
Reported as:
Median · Months
Time to Achieve PASI 90
MonthsMSB11022 (Core Treatment Period)EU-Humira
Time to Achieve PASI 903.4 ± 0.72.6 ± 1.4
SecondaryTime to Achieve PASI 100

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 100% improvement in PASI from baseline was measured.

Time frame:
Baseline (Day 1 of Core Treatment Period) up to Month 13.5
Reported as:
Median · Month
Time to Achieve PASI 100
MonthMSB11022 (Overall Treatment Period)EU-Humira/EU-Humira (Overall Treatment Period)EU-Humira/MSB11022 (Overall Treatment Period)
Time to Achieve PASI 1007.2 (0.7 to 11.8)7.2 (1.6 to 11.8)8.9 (1.6 to 11.8)
SecondaryNumber of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 16

PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

Time frame:
Baseline (Day 1 of Core Treatment Period), Week 16
Reported as:
Count of participants · Participants
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 16
ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Baseline- Moderate; Week 16- Clear5251
Baseline- Moderate; Week 16- Almost Clear7659
Baseline- Moderate; Week 16- Mild1617
Baseline- Moderate; Week 16- Moderate21
Baseline- Severe; Week 16- Clear1620
Baseline- Severe; Week 16- Almost Clear2726
Baseline- Severe; Week 16- Mild1216
Baseline- Severe; Week 16- Moderate21
SecondaryNumber of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 24

PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

Time frame:
Baseline (Day 1 of Extended Treatment Period), Week 24
Reported as:
Count of participants · Participants
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 24
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Baseline- Moderate; Week 24- Clear692525
Baseline- Moderate; Week 24- Almost Clear522431
Baseline- Moderate; Week 24- Mild21107
Baseline- Moderate; Week 24- Moderate220
Baseline- Severe; Week 24- Clear18119
Baseline- Severe; Week 24- Almost Clear271413
Baseline- Severe; Week 24- Mild966
Baseline- Severe; Week 24- Moderate211
Baseline- Severe; Week 24- Severe010
SecondaryNumber of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 52

PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).

Time frame:
Baseline (Day 1 of Extended Treatment Period), Week 52
Reported as:
Count of participants · Participants
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 52
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Baseline- Moderate; Week 52- Clear742934
Baseline- Moderate; Week 52- Almost Clear401316
Baseline- Moderate; Week 52- Mild17116
Baseline- Moderate; Week 52- Moderate404
Baseline- Moderate; Week 52- Missing100
Baseline- Severe; Week 52- Clear291716
Baseline- Severe; Week 52- Almost Clear1566
Baseline- Severe; Week 52- Mild373
Baseline- Severe; Week 52- Moderate322
Baseline- Severe; Week 52- Severe100
Baseline- Severe; Week 52- Missing100
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 16

Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline (Day 1 of Core Treatment Period) up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 16
ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Participants with TEAEs114117
Participants with Serious TEAEs86
Participants with TEAEs of special interest23
Participants with TEAEs Leading to Death00
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 54

Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline (Day 1 of Extended Treatment Period) up to Week 54
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 54
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Participants with TEAEs1426563
Participants with Serious TEAEs1234
Participants with TEAEs of special interest1014
Participants with TEAEs Leading to Death010
PrimaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI-75 response is defined as the percentage of participants who achieved at least a 75% improvement in PASI score from Baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16
Percentage of ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 1689.791.6
Statistical analysis
  • MSB11022 (Core Treatment Period) vs EU-Humira · Percentage difference: -1.9 · 95% CI -7.82 to 4.07
SecondaryNumber of Participants With Clinically Meaningful Differences in Laboratory Values

Based on categories of low, normal, or high according to the laboratory normal ranges, there were no clinically meaningful differences across the treatment groups in the numbers of participants with shifts in Laboratory parameters including hematology, chemistry and urinalysis from normal at Core Baseline to either low or high during the overall treatment period. Clinical meaningful was determined by the investigator.

Time frame:
Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Differences in Laboratory Values
ParticipantsMSB11022 (Core Treatment Period)MSB11022 (Extended Treatment Period)EU-HumiraEU-Humira/EU-HumiraEU-Humira/MSB11022
Number of Participants With Clinically Meaningful Differences in Laboratory Values00000
SecondaryNumber of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 16

Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 16
ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Participants with Negative ANA values205190
Participants with Positive ANA values610
Participants with Negative anti-ds DNA values201186
Participants with Intermediate anti-ds DNA values45
Participants with Positive anti-ds DNA values46
SecondaryNumber of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 24, 32, 40 and 52

Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.

Time frame:
Week 24, 32, 40 and 52
Reported as:
Count of participants · Participants
Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 24, 32, 40 and 52
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 24: Negative ANA1888992
Week 32: Negative ANA1868588
Week 40: Negative ANA1788585
Week 52: Negative ANA1858479
Week 24: Positive ANA1355
Week 32: Positive ANA1337
Week 40: Positive ANA1867
Week 52: Positive ANA838
Week 24: Negative anti-dsDNA1918988
Week 32: Negative anti-dsDNA1848386
Week 40: Negative anti-dsDNA1798684
Week 52: Negative anti-dsDNA1738179
Week 24: Positive anti-dsDNA835
Week 32: Positive anti-dsDNA835
Week 40: Positive anti-dsDNA1037
Week 52: Positive anti-dsDNA1127
Week 24: Intermediate anti-dsDNA331
Week 32: Intermediate anti-dsDNA722
Week 40: Intermediate anti-dsDNA721
Week 52: Intermediate anti-dsDNA842
SecondaryNumber of Participants With Clinically Meaningful Differences in Vital Signs

Number of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.

Time frame:
Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Differences in Vital Signs
ParticipantsMSB11022 (Core Treatment Period)MSB11022 (Extended Treatment Period)EU-HumiraEU-Humira/EU-HumiraEU-Humira/MSB11022
Number of Participants With Clinically Meaningful Differences in Vital Signs00000
SecondaryNumber of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG)

Number of participants with clinically significant abnormalities in 12-ECG were reported. Clinical significance was determined by the investigator.

Time frame:
Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG)
ParticipantsMSB11022 (Core Treatment Period)MSB11022 (Extended Treatment Period)EU-HumiraEU-Humira/EU-HumiraEU-Humira/MSB11022
Number of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG)01011
SecondaryDermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).

Time frame:
Weeks 16
Reported as:
Mean · Units on a scale
Dermatology Life Quality Index (DLQI) at Week 16
Units on a scaleMSB11022 (Core Treatment Period)EU-Humira
Dermatology Life Quality Index (DLQI) at Week 162.4 ± 3.22.5 ± 3.7
SecondaryDermatology Life Quality Index (DLQI) at Week 24 and 52

The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).

Time frame:
Week 24 and 52
Reported as:
Mean · Units on a scale
Dermatology Life Quality Index (DLQI) at Week 24 and 52
Units on a scaleMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 242.5 ± 4.12.3 ± 4.02.3 ± 3.9
Week 523.0 ± 4.72.1 ± 3.52.7 ± 4.0
SecondaryEuropean Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 16

The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).

Time frame:
Week 16
Reported as:
Mean · Units on a scale
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 16
Units on a scaleMSB11022 (Core Treatment Period)EU-Humira
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 160.9 ± 0.10.9 ± 0.1
SecondaryEuropean Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 24 and 52

The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).

Time frame:
Week 24 and 52
Reported as:
Mean · Units on a scale
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 24 and 52
Units on a scaleMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 240.8 ± 0.10.9 ± 0.10.9 ± 0.1
Week 520.9 ± 0.10.9 ± 0.10.8 ± 0.1
SecondaryEuropean Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 16

The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

Time frame:
Week 16
Reported as:
Mean · Units on a scale
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 16
Units on a scaleMSB11022 (Core Treatment Period)EU-Humira
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 1681.9 ± 13.983.1 ± 15.0
SecondaryEuropean Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on VAS Score at Week 24 and 52

The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

Time frame:
Week 24 and 52
Reported as:
Mean · Units on a scale
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on VAS Score at Week 24 and 52
Units on a scaleMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 2483.2 ± 14.284.2 ± 13.784.3 ± 13.9
Week 5283.5 ± 15.585.1 ± 13.282.1 ± 16.1
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI) at Week 16

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Week 16
Reported as:
Mean · Units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 16
Units on a scaleMSB11022 (Core Treatment Period)EU-Humira
Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 160.3 ± 0.40.3 ± 0.4
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI) at Week 24, and 52

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Week 24 and 52
Reported as:
Mean · Units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24, and 52
Units on a scaleMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 240.3 ± 0.40.2 ± 0.50.4 ± 0.3
Week 520.3 ± 0.40.1 ± 0.20.5 ± 0.3
SecondaryPatient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 16

Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.

Time frame:
Week 16
Reported as:
Mean · millimeter (mm)
Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 16
millimeter (mm)MSB11022 (Core Treatment Period)EU-Humira
Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 1626.9 ± 28.324.6 ± 24.3
SecondaryPatient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 24 and 52

Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.

Time frame:
Week 24 and 52
Reported as:
Mean · mm
Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 24 and 52
mmMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 2429.7 ± 25.320.6 ± 27.124.9 ± 20.5
Week 5225.0 ± 20.314.7 ± 16.529.5 ± 19.6
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 16

Number of participants with treatment emergent Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab were reported from baseline to week 16. Data was collected using validated bioanalytical method.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 16
ParticipantsMSB11022 (Core Treatment Period)EU-Humira
Participants with ADAs186179
Participants with Neutralizing Abs7070
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 24, 32, 40 and 52

Number of participants With positive treatment emergent Anti-Drug Antibodies (ADAs) and positive Neutralizing Antibodies (NAbs) to Adalimumab were reported. Data was collected using validated bioanalytical method.

Time frame:
Week 24, 32, 40 and 52
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 24, 32, 40 and 52
ParticipantsMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 24: ADAs1858990
Week 32: ADAs1707885
Week 40: ADAs1617280
Week 52: ADAs1626877
Week 24: NAb784239
Week 32: NAb673032
Week 40: NAb702928
Week 52: NAb632930
SecondaryAnti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 16

Anti-Drug Antibodies (ADAs) Titers for adalimumab at week 16 was reported. Data was collected using validated bioanalytical method.

Time frame:
Week 16
Reported as:
Median · Titers
Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 16
TitersMSB11022 (Core Treatment Period)EU-Humira
Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 168.0 ± 18.0 ± 1
SecondaryAnti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 24, 32, 40 and 52

Anti-Drug Antibodies (ADAs) Titers for adalimumab at Week 24, 32, 40 and 50 was reported. Data was collected using validated bioanalytical method.

Time frame:
Week 24, 32, 40 and 52
Reported as:
Median · Titers
Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 24, 32, 40 and 52
TitersMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 2416.0 (1 to 4096)16.0 (1 to 4096)16.0 (1 to 4096)
Week 3216.0 (1 to 1024)16.0 (1 to 8192)16.0 (1 to 16384)
Week 4016.0 (1 to 8192)16.0 (1 to 8192)16.0 (1 to 16384)
Week 528.0 (1 to 4096)16.0 (1 to 4096)8.0 (1 to 4096)
SecondaryObserved Serum Concentration at Week 16

Observed serum concentrations at week 16 were reported.

Time frame:
Week 16
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Observed Serum Concentration at Week 16
Nanogram per milliliter (ng/mL)MSB11022 (Core Treatment Period)EU-Humira
Observed Serum Concentration at Week 166990 ± 45046410 ± 4152
SecondaryObserved Serum Concentration at Week 24 and 52

Observed serum concentrations at week 24 and 52 were reported.

Time frame:
Week 24 and 52
Reported as:
Geometric mean · ng/mL
Observed Serum Concentration at Week 24 and 52
ng/mLMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Week 246240 ± 45695870 ± 45166430 ± 4610
Week 526910 ± 57505930 ± 45296600 ± 5394

Adverse events

Collected over Core Treatment period: Baseline up to Week 16; Extended Treatment Period: Baseline up to Week 54. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSB11022 (Core Treatment Period)0/221 (0%)8/221 (3.6%)30/221 (13.6%)
EU-Humira0/220 (0%)6/220 (2.7%)34/220 (15.5%)
MSB11022 (Extended Treatment Period)0/213 (0%)12/213 (5.6%)59/213 (27.7%)
EU-Humira/EU-Humira1/101 (1%)3/101 (3%)32/101 (31.7%)
EU-Humira/MSB110220/101 (0%)4/101 (4%)25/101 (24.8%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventMSB11022 (Core Treatment Period)EU-HumiraMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
Cardiac failureCardiac disorders0/2210/2200/2132/1010/101
Hypertensive cardiomyopathyCardiac disorders0/2210/2200/2131/1010/101
Mitral valve incompetenceCardiac disorders0/2210/2200/2131/1010/101
Myocardial infarctionCardiac disorders0/2210/2200/2130/1011/101
Conjunctival cystEye disorders0/2210/2200/2130/1011/101
AppendicitisInfections and infestations0/2210/2200/2130/1011/101
PneumoniaInfections and infestations0/2210/2200/2131/1010/101
Staphylococcal abscessInfections and infestations0/2210/2200/2130/1011/101
Brain oedemaNervous system disorders0/2210/2200/2131/1010/101
Cerebral haematomaNervous system disorders0/2210/2200/2131/1010/101
Most frequent other events
Most frequent other events
EventMSB11022 (Core Treatment Period)EU-HumiraMSB11022 (Extended Treatment Period)EU-Humira/EU-HumiraEU-Humira/MSB11022
NasopharyngitisInfections and infestations13/22115/22031/21312/10116/101
PsoriasisSkin and subcutaneous tissue disorders0/2210/22011/21310/1013/101
Injection site erythemaGeneral disorders11/22113/2209/2135/1016/101
Injection site painGeneral disorders11/22111/22012/2134/1015/101
Upper respiratory tract infectionInfections and infestations0/2210/22011/2135/1014/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)MSB11022 (Core Treatment Period)EU-HumiraTotal
Mean44.5 ± 12.842.7 ± 12.043.6 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)MSB11022 (Core Treatment Period)EU-HumiraTotal
Female7573148
Male147148295
Race
Race(Participants)MSB11022 (Core Treatment Period)EU-HumiraTotal
White205200405
Black or African American213
Asian5914
American Indian or Alaska Native10818
Native Hawaiian or Other Pacific Islander000
Other011
Missing/Not collected at this site022
Ethnicity
Ethnicity(Participants)MSB11022 (Core Treatment Period)EU-HumiraTotal
Hispanic or Latino232346
Not Hispanic or Latino199196395
Missing022
08

Study locations

76 sites
  • San Luis Dermatology & Laser Clinic, Inc.
    San Luis Obispo, California 93405, United States
  • Florida Academic Centers Research and Education
    Coral Gables, Florida 33134, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Modern Research Associates
    Dallas, Texas 75231-5945, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • DCC 'Sveti Georgi' EOOD
    Haskovo, 6300, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • DCC "Sv. Georgi", EOOD
    Plovdiv, 4000, Bulgaria
  • Diagnostic Consultative Center II - Sofia OOD
    Sofia, 1040, Bulgaria
  • MC "Robert Koch", EOOD
    Sofia, 1407, Bulgaria
  • Medical Center "Excelsior", OOD
    Sofia, 1407, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • UMHAT "Alexandrovska" EAD
    Sofia, 1431, Bulgaria
  • Military Medical Academy - MHAT - Sofia
    Sofia, 1606, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • DCC 3 - Varna, EOOD
    Varna, 9023, Bulgaria
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Dr. Lorne E. Albrecht, Inc.
    Surrey, British Columbia V3V 0C6, Canada
  • Gupta, Aditya K. MD
    London, Ontario N5X 2P1, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research
    Mississauga, Ontario L5H 1G9, Canada
  • Dr Melinda Gooderham Medicine Professional Corporation
    Peterborough, Ontario K9J 5K2, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain
    Ste-Foy, Quebec G1V 4X7, Canada
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • Nemocnice Novy Jicin a.s.
    Novy Jicin, 741 01, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Clintrial, s.r.o.
    Praha 10, 100 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Dermatovenerologická klinika
    Praha 8 - Liben, 180 81, Czechia
  • Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem
    Usti nad Labem, 40113, Czechia
  • Vahlberg & Pild OÜ
    Tallinn, 10134, Estonia
  • East Tallinn Central Hospital
    Tallinn, 11312, Estonia
  • Clinical Research Centre
    Tartu, 50106, Estonia
  • Tartu University Hospital
    Tartu, 50417, Estonia
  • CHU Nice - Hôpital de l'Archet 2
    Nice cedex 3, Alpes Maritimes 06202, France
  • Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Haut Lévêque
    Bordeaux, Gironde 33000, France
  • Hôpital de Brabois Adultes
    Vandoeuvre les Nancy, Meurthe Et Moselle 54511, France
  • Hôpital de la Timone
    Marseille cedex 5, 13385, France
  • Licca
    Augsburg, Bayern 86179, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet
    Frankfurt, Hessen 60590, Germany
  • Universitaetsklinikum Bonn AoeR
    Bonn, Nordrhein Westfalen 53105, Germany
  • Praxis fuer Dermatologie und Venerologie
    Dresden, Sachsen 01097, Germany
  • Clinical Research Hamburg GmbH
    Hamburg, 22143, Germany
  • Ambrozia Gondozohaz Szolg. Nonprofit Kft.
    Budapest, 1238, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
    Nyiregyhaza, 4400, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • ALLERGO-DERM BAKOS Kft.
    Szolnok, 5000, Hungary
  • Unidad de Investigacion de las Enfermedades Reumaticas
    Cuauhtemoc, Distrito Federal 06090, Mexico
  • Clinical Research Institute S.C.
    Tlalnepantla, Estado De Mexico 54055, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Dermatologia de Monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Köhler & Milstein Research S.A de C.V.
    Merida, Yucatán 97000, Mexico
  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan
    Merida, Yucatán 97070, Mexico
  • Derma Norte del Bajio S.C.
    Aguascalientes, 20127, Mexico
  • Centrum Kliniczno - Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
    Elblag, 82-300, Poland
  • Gdanskie Centrum Zdrowia Sp. z o.o.
    Gdansk, 80-542, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-349, Poland
  • Grazyna Pulka Specjalistyczny Osrodek "ALL-MED"
    Krakow, 31-023, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
    Lodz, 90-242, Poland
  • NZOZ ALL-MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
    Lodz, 94-048, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Med-Laser"
    Lublin, 20-406, Poland
  • Centrum Badan Klinicznych S.C.
    Poznan, 60-773, Poland
  • Centrum Medyczne Medyk
    Rzeszow, 35-055, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z
    Torun, 87-100, Poland
  • SP Szpital Kliniczny Nr 1 we Wroclawiu
    Wroclaw, 50-368, Poland
  • Centrum Medyczne ADAMAR
    Wroclaw, 53-658, Poland
  • SBEI HPE "Kazan State Medical University" of the MoH of the RF
    Kazan, 420012, Russian Federation
  • LLC "Alliance Biomedical - Russian Group"
    Saint-Petersburg, 196191, Russian Federation
  • Clinic of skin and veneral diseases
    Saratov, 410028, Russian Federation
  • SBEI HPE "Yaroslavl State Medical University" of the MoH of the RF
    Yaroslavl, 150000, Russian Federation
  • Royal Stoke University Hospital
    Stoke on Trent, Staffordshire ST4 6QG, United Kingdom
  • Russells Hall Hospital
    Dudley, West Midlands DY1 2HQ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Dec 2016, 10 months.

Results were first posted in Feb 2019, 2 years 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2016
First posted
Jan 21, 2016
StartActual
Feb 16, 2016
Primary completionActual
Dec 31, 2016
CompletionActual
Dec 18, 2017
Results first posted
Feb 19, 2019
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02660580
Responsible party
Sponsor
First posted
Jan 21, 2016
Start date
Feb 16, 2016
Primary completion
Dec 31, 2016
Completion
Dec 18, 2017
Results posted
Feb 19, 2019
Last update
Dec 27, 2023

Study contacts

Medical Responsible
study director · Fresenius Kabi Swiss BioSim GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion